Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease

NCT02973360 is registered in ClinicalTrials.gov with Micelle BioPharma Inc as lead sponsor.

NCT NCT02973360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02973360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease
Lead sponsor
Micelle BioPharma Inc
Phase
Phase 2
Overall status
Unknown status
Start date
March 2, 2017
Completion date
January 2, 2022
Enrollment
68 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease